Page 200 - Hospital Authority Convention 2018

Corporate Scholarship Presentations
HOSPITAL AUTHORITY CONVENTION 2018

C3.6 Chronic Disease Management 14:30 Room 428

2
Pharmacist-managed Clinic Targeting Patients with HER -positive Breast Cancer: The Local and UK Experience
Yuen CM
Pharmacy Department, Queen Mary Hospital, Hong Kong

With the advances in understanding tumor biology, treatment paradigm for breast cancer has evolved significantly in the
past few decades. Many novel agents, which have demonstrated survival benefits, have been developed. Among the breast
cancer subtypes, human epidermal growth factor receptor 2 (HER2) positive breast cancers are accounted for about 20%
of cases. With promising clinical outcomes and tolerable side effect profile of the new HER2 targeted agents such as
Trastuzumab, HER2-positive breast cancer has become a chronic and manageable disease with durable responses for many
patients.
As HER2 targeted agents have become the standard of care and have relatively long treatment duration, population receiving
Trastuzumab is expanding. Considering the stable patient characteristics for this group, clinical pharmacists’ input to reduce
oncologists’ workload, measures to streamline administration process and optimise patient care is seemingly beneficial. In
the United Kingdom, for instance, the Trastuzumab homecare service has been piloted in the Royal Marsden Hospital to cope
with the increasing population, reducing Chemotherapy Unit chair time and also enhancing the quality of care to patients.

In Hong Kong, multidisciplinary care in oncology has also been advocated and the setting up of Pharmacist-managed Clinics
in Hospital Authority is one of such initiatives. In Queen Mary Hospital, the Oncology Pharmacist-managed Trastuzumab
Clinic is established to target patients on adjuvant maintenance Trastuzumab therapy. The implementation of such service
aims to enhance the safety and quality of adjuvant Trastuzumab therapy for patients with early breast cancer through the
integrated care of oncologists and oncology pharmacists. The service will also shorten the waiting time for cancer patients
and reduce the workload of oncologists.

Tuesday, 8 May 2018

198